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Many factors during the transplantation process inﬂuence posttransplant graft function and survival, including donor type and age,
graft preservation methods (cold storage, machine perfusion), and ischemia-reperfusion injury. Successively, they will lead to
cellular and molecular alterations that determine cell and ultimately organ fate. Oxidative stress and autophagy are implicated in
posttransplant outcome since they are both aﬀected by the stress responses triggered in each step (donor, preservation, and
recipient) of the transplantation process. Furthermore, oxidative stress inﬂuences autophagy and vice versa. Interestingly, both
processes have positive as well as negative eﬀects on graft outcome, suggesting they are tightly linked during the transplantation
process. In this review, we discuss the importance, regulation and crosstalk of oxidative signals, and autophagy in the ﬁeld of
transplantation medicine.
1. Introduction
For patients with end-stage organ disease, organ transplan-
tation has become the treatment of choice. However, the
success of transplantation is limited by a global shortage
of suitable organs as well as loss of grafts following trans-
plantation due to primary nonfunction or rejection. The
gap between supply and demand has steadily increased
over the years and, as a result, so has the number of
patients on the waiting list [1, 2]. This is an alarming
increase, as organ transplantation signiﬁcantly improves a
patient’s quality of life as well as survival rate when com-
pared to patients who remain on the waiting list [3–5].
These problems can be addressed by increasing the use
of older and higher risk donors, while simultaneously
improving graft longevity.
Oxidative stress levels correlate with graft survival in all
steps of the transplantation process including in the donor
[6–16], during preservation [17, 18], and reperfusion in the
recipient. In donation after brain death (DBD) donors, brain
death pathophysiology leads to increased renal oxidative
damage markers which correlate with acute rejection,
delayed graft function (DGF), and allograft function [6–16].
In donation after cardiac death (DCD) donors, cardiac arrest
causes warm ischemia which is associated with impaired
graft function and higher mortality rates [6–8]. Increased
oxidative stress markers are evident in organs from DCD
donors, but no evidence is available correlating them with
the outcome. Clinically proven donor treatments that beneﬁt
graft survival include dopamine administration and hypo-
thermic cooling of DBD donors, of which the eﬀects could
be related to modulation of oxidative stress [19, 20].
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Organ grafts suﬀer additional ischemic injury during
preservation. Prolonged duration of cold ischemia is consid-
ered an independent risk factor for a nonfunctioning or dys-
functioning transplant, particularly in marginal or extended
criteria donation (ECD) donors [21]. These side eﬀects have
recently led to the implementation of hypothermic machine
perfusion (HMP). HMP has clear beneﬁts over static cold
storage, as evidenced by improved graft function and survival
rates in kidney transplantation [22, 23], as well as reduced
oxidative stress markers in experimental [24, 25] and clinical
[26] liver preservation.
In the recipient, the mechanism of reperfusion injury,
labeled ischemia-reperfusion (IR) injury (IRI), has been
reported in most solid transplantable organs [27–31] and is
mediated by reactive oxidative species (ROS) production
most likely from donor-derived vascular cells [32, 33],
followed by a second burst of ROS probably produced by
the recipient’s phagocytes [29, 34–40]. However, mitochon-
dria are also implicated in ROS [29, 41–44] as well as
nitric oxide (NO) production during IRI [45–47]. Despite
overwhelming experimental evidence on the beneﬁcial
eﬀects of attenuating ROS during this phase, clinical evidence
remains limited.
Oxidative stress is a known inducer of autophagy. Even
though autophagy regulation during the transplantation pro-
cess is only starting to be understood, several autophagy
modulators have already been implemented. In this review,
we will ﬁrst introduce autophagy in the context of the trans-
plantation process and cover the current knowledge during
each of these stages. Secondly, we will touch upon the com-
plex, intertwined, and reciprocal relationship of oxidative
stress and autophagy in the ﬁeld of transplantation medicine
while covering the therapeutic strategies that target each of
these pathways.
2. Autophagy and Transplantation
2.1. Autophagy: Importance and Mechanisms. Several path-
ways of autophagy exist [48], of which macroautophagy is
the best studied (and which will simply be referred to as
“autophagy” for the remainder of this manuscript). It
involves the formation of double-membranous vesicular
“autophagosomes” that occlude and transport the soon-to-
be degraded material to the lysosomes (Figure 1). This
process is normally constitutively active in cells, albeit at a
low basal level, thereby maintaining cellular homeostasis
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Figure 1: Overview of the autophagy process. Autophagy is initiated by the ULK1 complex, which is negatively regulated by mTOR, but
positively by AMPK. This way it responds to nutrient or energy deprivation. In addition, class III PI3K complex requires Beclin 1, which
is inhibited by Bcl-2. During elongation, Atg5-Atg12 and LC3-II are required. The latter is attached to the autophagosomal membranes.
LC3-II will be delipidated on the outer membrane by Atg4 (a process inhibited by H2O2) but remains on the inner membrane and will be
degraded inside the lysosomes. Mitochondria can be also degraded (mitophagy), via recruitment of Sqstm1/p62. The latter protein also
recruits Keap1 for degradation, thereby enabling Nrf-2-dependent antioxidant transcription. Eventually, autophagosomes fuse with
lysosomes, the cellular structures in which degradation takes place. The levels of autophagy determine the outcome on cellular injury and
need to stay balanced in order not to provoke death.
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(Figure 1). However, autophagy is stimulated upon stress
through several signaling pathways, of which the mammalian
target of rapamycin (mTOR) pathway is the most notable in
response to nutrient stress. Energy deprivation attenuates
mTOR signaling through the activation of AMP-activated
kinase (AMPK), which also directly stimulates autophagy
by the phosphorylation of the autophagy-initiating ULK1
complex. Another initiation complex is constituted by
Vps34 (class III PI3K) and Beclin 1, an autophagy-speciﬁc
BH3-only domain-containing protein that is inhibited by
several antiapoptotic Bcl-2 family proteins (Figure 1). As
such, apoptotic signals can also trigger autophagy, in
which the autophagic response often precedes apoptosis
as the ﬁrst attempt to survival [49]. However, when
autophagy fails, cells will eventually activate apoptosis,
which may even occur with the help of the still active
autophagic machinery. This shows that autophagy may
switch from a prosurvival to a prodeath pathway under
certain conditions [50], although the exact mechanism,
context, and details on this autophagy-dependent cell
death remain currently elusive.
Following initiation, the formation of autophagosomes is
mediated by the Atg5-Atg12 complex and the formation of
phosphatidylethanolamine-conjugated LC3 (“LC3-PE” or
“LC3-II”) (Figure 1). The latter is generally used as a marker
for autophagy, as it is distinguishable from its precursor LC3-
I on Western blot and its ﬂuorescent labeling allows visuali-
zation of autophagosomes as GFP-LC3 punctae. Despite
delipidation of LC3-II on the outer membrane by Atg4,
LC3-II remains attached to the inner autophagosomal mem-
branes even after fusion of autophagosomes with lysosomes.
Therefore, an increase of LC3-II or GFP-LC3 punctae can
signify stimulation of autophagy or attenuation of the ﬁnal
steps in autophagy (e.g., inhibition of fusion), leading to
an accumulation of autophagosomes without any true
upregulation of autophagy. Therefore, prudency is advised
when interpreting autophagy data because the dynamic
character of the “autophagic ﬂux” should be taken into
consideration [51].
As the graft endures several types of stress during trans-
plantation, it is evident that the protective properties of
autophagy might be important in restoring cellular homeo-
stasis and function in the organ grafts. Interestingly, DGF
increases with donor (and recipient) age as aging leads to
increased susceptibility towards cellular stress [52, 53]. An
underlying mechanism for this increased vulnerability of
aged organs is the age-related reduction in autophagy [52].
It has therefore been suggested that pharmacological
stimulation of autophagy could reduce graft injury and
promote function [54]. However, as excessive autophagy
may detrimentally impact cellular fate through autophagy-
dependent cell death (Figure 1), it is important to ﬁrst under-
stand the dynamics and role of autophagy to determine
whether autophagy stimulation or inhibition is the best
option in transplantation.
2.2. Autophagy in the Donor. The autophagic response in the
donor is likely the result of donor-related characteristics
including donor age, gender, comorbidities, and donor type
of death. Of course, ischemic time is strongly prolonged in
DCD compared to DBD grafts, which could partially explain
the stronger injury in DCD grafts. This is important, since
autophagy’s dynamics and role (protective versus detrimen-
tal) during ischemic stress are likely dependent on the extent
of ischemic injury, at least in the kidney [55, 56] and heart
[57]. As DCD donors suﬀer more extensive anoxic injury
compared to DBD donors, this could trigger autophagy-
dependent cell death (Figure 2) and suggests that therapeutic
strategies involving autophagy modulation are strongly
donor type-dependent.
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Figure 2: Regulation of oxidative signals and autophagy by transplantation-related factors. Excessive autophagy and/or oxidative stress can
lead to increased graft injury and tilt the balance to the right. To tilt the balance towards survival, excessive signals need to be reduced towards
protective levels of oxidative signals and autophagy.
3Oxidative Medicine and Cellular Longevity
Additionally, the higher posttransplant injury in ECD
(e.g., older) kidneys may be attributed to a decline in autoph-
agic activity with age [58–61], justifying autophagy stimula-
tion as the preferred strategy in these donors. Compared to
young mice, old mice showed a decreased autophagic
response in terms of vacuole formation and elimination after
stimulation of these processes with vinblastine and Triton
X-100 [60]. In line with this, hypoxia-induced injury was
reduced by starvation-induced autophagy in older kidneys
[62]. Besides donor age, a less studied but seemingly equally
important feature is the gender of the donor. In a cardiac
IRI study in mice, males and females showed diﬀerent
autophagic activities: male mice show a decrease, and female
mice an increase in LC3-II levels [61]. We have also observed
gender diﬀerences in the kidney, with a decrease in male, but
unchanged LC3-II levels in female Sprague-Dawley rats sub-
jected to 45min of ischemia followed by 3h of reperfusion
(Figure 3). As such, therapeutic strategies involving autoph-
agy modulation may diﬀer in organs coming from male
and female donors (Figure 2).
2.3. Autophagy during Organ Preservation. Mixed reports
exist on the eﬀects of cold ischemia on autophagy. In mouse
kidneys, cold ischemia resulted in increased autophagy
markers [63]. Interestingly, repression of autophagic ﬂux by
means of lysosomal inhibitor baﬁlomycin A1 resulted in less
apoptosis, suggesting that autophagy could trigger cell death
during renal cold ischemia. Similar ﬁndings were observed in
cold-preserved rat lungs [61], where prolonged preservation
resulted in increased autophagy associated with cell death.
Alternatively, decreased markers of autophagy were found
following cold ischemia in marginal, steatotic rat livers
[64–66]. Induction of autophagy in these marginal livers by
means of melatonin and trimetazidine addition to the cold
preservation medium improved organ quality as evidenced
by lower levels of injury markers ALT and GLDH [66]. These
beneﬁts were attenuated when autophagy was suppressed
with baﬁlomycin A1 [66]. Furthermore, oxygen insuﬄation
of the cold preservation medium of marginal livers reversed
the suppression of autophagy and functional impairment
[65], suggesting beneﬁcial eﬀects of autophagy induction.
These studies suggest that the diﬀerential eﬀects of autophagy
activation might be organ-dependent (Figure 2; see also
Autophagy in the Recipient) and closely associated with
organ function and cell death.
2.4. Autophagy in the Recipient. The role of autophagy in
IRI is best studied in the context of the transplantation pro-
cess. However, its dynamics and roles remain elusive and
are likely dependent on diﬀerent factors. Firstly, when
studying the nature of autophagy dynamics, that is, whether
autophagy is stimulated or attenuated during IRI, research
suggests that autophagy is mostly upregulated in the heart
[67] and the kidney [55], while ﬁndings in the liver are
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Figure 3: Gender diﬀerences in autophagy activation in response to ischemia-reperfusion injury. Western blot expression of autophagy-
related proteins LC3-I, LC3-II, and Sqstm1/p62 in female and male Sprague-Dawley rat kidneys subjected to 45min of warm ischemia
(WI) followed by 3 h of reperfusion (3 h R). Each lane represents an independent experiment (N = 6). Quantiﬁcation of p62 or LC3-II
over GAPDH levels, compared to the mean of the corresponding Sham group. LC3-II and p62 are clearly lower in the WI group of
females compared to the male WI group. Results are presented as mean± SD (N = 6 per group) (∗p < 0 05; ∗∗∗p < 0 001).
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conﬂicting [64]. These discrepancies might be explained by
several reasons (described in more detail in [55]), including
the diﬃculty of measuring the dynamic process of autoph-
agic ﬂux in static samples. Indeed, an increase in LC3-II
could equally well indicate stimulated autophagy as well
as inhibited autophagic ﬂux. In vivo experiments with
chloroquine (an inhibitor of autophagosome-lysosome
fusion, mimicking inhibited autophagic ﬂux) suggest that
autophagy inhibition might occur in the heart [68] and liver
[69]. Moreover, as autophagy often ﬂuctuates during pro-
longed stress, multiple time point postreperfusion should be
investigated [55].
Secondly, conﬂicts arise when looking at the proposed
role of autophagy during IRI. In hepatic IRI models, most
studies indicate a protective role for autophagy [64], whereas
both protective and detrimental roles are assigned to autoph-
agy in the heart and kidney [55, 67]. Besides the diﬃculties in
measuring autophagic ﬂux, nonspeciﬁc chemical modulators
of autophagy also have secondary eﬀects on mTOR (e.g.,
rapamycin), PI3K (e.g., 3-methyladenine), or lysosomal and
endocytic function (baﬁlomycin A1 and chloroquine) [55].
Even data in conditional autophagy knockout mice (e.g.,
atg5−/−) are important to interpret with caution. As autoph-
agy is an important mechanism for basal cellular homeostasis
in cells (Figure 1), any stress addition in these models will
likely lead to more injury than in wild-type. In this context,
proximal tubule-speciﬁc Atg5 KO mice displayed strange
concentric membranous structures in targeted cells [70],
suggesting unhealthy cells.
Thirdly, several reports propose a dual role for autophagy
in IRI, dependent of the extent of the stress [55, 71]; that is,
mild IR stress leads to protective autophagy stimulation,
while severe stress could trigger a switch towards
autophagy-dependent cell death (Figures 1 and 2). In this
respect, the duration of ischemia prior to transplantation is
an important factor to consider. The longer the ischemic
period, the more severe the reperfusion injury, which seems
associated mostly with a detrimental role for autophagy, at
least in the kidneys [55]. Besides the extent of the stress, the
type of stress that initiates autophagy is also important. This
is evident in the heart, where autophagy-dependent cell death
during reperfusion seems to be dependent on the levels of
Beclin 1, in which initiation is likely determined by apoptotic
factors. Protective autophagy on the other hand seems to be
dependent on AMPK activation and would therefore be
related to changes in energy status (Figure 2) [71].
Finally, autophagy during IRI is strongly determined by
the degree of autophagy dependency of the organs and even
of diﬀerent cell types within an organ (Figure 2). In renal
podocytes, for example, autophagy is much more important
for cellular homeostasis (as these cells are postmitotic) than
in tubular cells. Also, cardiomyocytes are strongly dependent
on basal autophagy, while hepatocytes rely more on stress-
induced autophagy. In this respect, liver cells might have
diﬀerent mechanisms controlling autophagy as they can
tolerate more severe stress than other organs. This might
explain the more consistent data regarding the protective role
for autophagy in this organ compared to the kidney and the
heart during IR.
3. Autophagy and Oxidative
Stress in Transplantation
3.1. The Relationship between Autophagy and Oxidative
Stress. Both oxidative stress and autophagy have been
described as both protective and detrimental pathways in
response to cellular stressors [34, 55]. Therefore, it is feasible
that the ﬁne balance of oxidative stress levels and autophagy
activation plays an important role in the long-term function
and survival of organ grafts. This makes modulation of these
pathways interesting targets to predict or improve graft func-
tion and survival after transplantation.
Surprisingly, the only currently known direct redox-
based regulation of autophagy is the inhibitory oxidation of
Atg4 by H2O2, which suppresses the delipidation of LC3-II
[72] (Figure 1). Furthermore, H2O2 is also proposed to stim-
ulate autophagy initiation directly via regulation of AMPK
[73] (Figure 1). In a slower, more indirect fashion, oxidative
stress also regulates transcription of Beclin 1 and LC3 [54].
Together, these protective, proautophagic eﬀects are
achieved with subtle changes in ROS. Conversely, acute and
persistent ROS production can oxidatively modify macro-
molecules in such a way that they are only partially degraded
by the autophagic/lysosomal pathway. This produces an
indestructible product known as lipofuscin, which accumu-
lates within the lysosomes, hampers their function, and
sustains or even exacerbates oxidative injury [74]. Together,
this suggests that the amount of ROS produced will deter-
mine whether autophagy will be activated or inhibited and
whether it prevents or ampliﬁes further damage.
Besides the regulation of autophagy by oxidative mole-
cules, autophagy reciprocally regulates oxidative signals. As
it is a clearance mechanism, autophagy may remove oxida-
tively damaged macromolecules or even entire organelles.
Upon excessive ROS production, mitochondria risk severe
damage and need to be partially removed [75]. This occurs
through the selective autophagic degradation of damaged
mitochondrial fragments called “mitophagy” (Figure 1). This
process involves the recruitment of PINK1 and Parkin to the
outer mitochondrial membrane where they promote ubiqui-
tination (Ub) of several mitochondrial proteins [76, 77]. This
Ub signal serves as a recognition for Sqstm1/p62, which is an
adapter protein for LC3-II (Figure 1). The link between ROS
and mitophagy was conﬁrmed in a study on heart failure in
mice, describing that p53-induced impairment of mitophagy
resulted in mitochondrial dysfunction and increased ROS
production [76, 77].
In addition to mitophagy, autophagy is shown to regulate
antioxidant responses through interactions of Sqstm1/p62
with Keap1. Sqstm1/p62 recruits Keap1 via interactions with
ubiquitinated aggregates, after which Keap1 is degraded
via autophagy. Degradation of Keap1 in turn prevents it
from ubiquitinating and degrading Nrf2-dependent tran-
scription factors, thereby enabling the antioxidant response
[78] (Figure 1).
3.2. Autophagy and Oxidative Stress in the Donor. The accu-
mulation of acute and chronic injuries in the donor leads to
increased senescence and reduced organ quality. In ECD
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donors, this may be due to an increase in age-related oxida-
tive damage (Figure 2) [16] as well as a reduction of autoph-
agic activity and hence the inability to remove oxidatively
damaged organelles. This link was shown in the kidneys of
aged rats, where a high caloric diet exacerbated oxidative
damage and aging, while autophagy was reduced [79]. The
opposite was observed in the low caloric group [79]. The link
between caloric intake and autophagy regulation is interest-
ing, as it highlights how energy deprivation (i.e., glucose and
amino acid stress) can initiate protection via autophagy-
mediated pathways to restore cellular energy supplies
(Figure 2) [73]. In response to starvation, increased activity
of the mitochondrial apparatus in turn increases mitochon-
drial ROS production, which activates autophagy [73]. Inter-
estingly, a proteomics study in brain-dead rodents indicated
that both metabolic changes and mitochondrial dysfunction
are the two major canonical pathways aﬀected in the kid-
ney of brain-dead donors [80]. Even though no direct line
of evidence connects these alterations to autophagy, it is
nonetheless feasible that autophagy is indeed modulated
in DBD donors.
A recent study from our group showed that the treatment
of brain-dead rats with thyroid hormone T3, both a meta-
bolic regulator and a powerful inducer of autophagy,
improved liver function, while reducing apoptosis and oxida-
tive stress [81]. In prosecution of this work [81], the protec-
tive eﬀects of T3 preconditioning in brain-dead rats were
indeed accompanied by an induction of autophagy in the
liver, as evidenced by increased formation of LC3-II together
with decreased (albeit nonsigniﬁcantly) levels of the autoph-
agic substrate SQSTM1/p62 (Figure 4). Interestingly, in the
kidney, T3 neither altered autophagy nor attenuated injury
or apoptosis (Figure 4). Therefore, this suggests that
T3-induced autophagy is not evident in the kidney and con-
sequently, neither a reduction in apoptosis nor injury. In
contrast, the reduction in apoptosis and injury markers in
the liver does appear to be associated with increased hepatic
autophagy, suggesting an important role for autophagy
stimulation in the livers from brain-dead animals. We
hypothesize that T3 boosts a transient peak in mitochondrial
activity and ROS production, resulting in autophagy induc-
tion and subsequent protective eﬀects during BD in the liver
(Figure 5). This is supported by a recent study by Sinha et al.
that showed that T3 induces autophagy via ROS-related
pathways in the liver both in vivo and ex vivo [82, 83]. This
phenomenon might not be evident in the brain-dead kidney
due to extensive levels of oxidative stress [11], which might
push the balance from a protective to a detrimental role for
autophagy. This work therefore suggests that triggering oxi-
dative pathways while simultaneously increasing autophagy
could be an interesting strategy to improve liver function in
DBD donors. In this respect, modulation of (mitochondrial)
metabolism by compounds such as T3 might be the key to
stimulation of transient ROS and subsequently protective
autophagy activation (Figure 2).
3.3. Autophagy and Oxidative Stress during Preservation.
Since most organs worldwide are still preserved on ice,
several developments have been made to reduce ischemic
injury during cold storage. The gold standard for preserva-
tion solutions in kidney, liver, pancreas and small bowel pres-
ervation is the University of Wisconsin (UW) storage
solution [22, 84]. When comparing UW to HTK solution,
the use of UW leads to decreased renal apoptosis and was
linked to lower graft injury in human renal allografts [85].
UW contains, besides energy supplies (adenosine) and
osmotic compounds, the antioxidants glutathione and allo-
purinol [84, 86] (Figure 2). However, the beneﬁcial eﬀects
of these compounds are questionable considering their short
life-spans and the fact that supplementation of glutathione to
UW solution was unable to improve renal transplantation
outcomes [84]. Nonetheless, a rodent study on kidney trans-
plantation showed that treatment with hydrogen-rich saline
(HRS), a novel antioxidant, immediately before ischemia
attenuated transplantation-related renal injury and oxidative
stress, while simultaneously inducing autophagic markers
Beclin 1 and LC3-II [87]. Inhibition of autophagy with chlo-
roquine attenuated these protective eﬀects of HRS, suggest-
ing that these eﬀects were indeed autophagy-mediated and
linked to oxidative stress [87]. Therefore, the addition of
antioxidants to the preservation solution remains an interest-
ing option to reduce graft injury (Figure 2). Conversely,
prolonged cold ischemia of healthy kidneys in UW solution
showed increased numbers of apoptotic and autophagic cells.
In this case, the addition of baﬁlomycin A1 inhibited both
autophagy and apoptosis [63]. These studies suggest that
for the kidney the extent of cold ischemia injury could dictate
whether either autophagy induction (in the case of shorter
cold ischemia times) or inhibition (in the case of prolonged
cold ischemia times) might be beneﬁcial (Figure 2).
In the liver, cold storage of hepatic cells inhibited
autophagic ﬂux in both UW and Celsior solutions. How-
ever, only Celsior-stored cells reactivated autophagy upon
reperfusion, while UW-stored cells displayed impaired
lyso-autophagosomal fusion and elevated cell death [88].
Interestingly, pretreatment with simvastatin before cold
ischemia led to the restoration of autophagy even in UW
solution. This was accompanied by preserved cellular viabil-
ity [88], suggesting possible beneﬁts for hepatocytes when
autophagy is induced during cold storage. These beneﬁts
might be linked to oxidative stress, as simvastatin-induced
autophagy in cold-stored rat steatotic livers was accompa-
nied by attenuation of oxidative stress [89], showing a link
between ROS reduction and autophagy induction during
cold liver preservation. In support of this, a study on liver
transplantation in which the preservation medium (IGL-1)
was enriched with trimetazidine, a fatty acid oxidation
inhibitor, showed reduced oxidative stress yet activation of
autophagy accompanied with reduced mitochondrial dam-
age and hepatic injury [90]. These data therefore suggest
that during cold storage of the liver, a strategy is preferred
that simultaneously attenuates oxidative stress and stimu-
lates autophagy.
The advantage of HMP over static cold storage has led to
an increased implementation of this technique in the clinical
setting. However, the lack of oxygen during HMP initiates
high metabolic ﬂux and subsequent high ROS production,
particularly during the ﬁrst minutes of reperfusion [91].
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Figure 4: Posttranscriptional reduction of apoptosis and induction of autophagy in the liver of brain-dead rats following T3 treatment, yet no
eﬀects in the kidney. Western blot expression of proapoptotic protein Bax and autophagy-related proteins LC3-II and SQSTM1/p62 in the
liver (a, c) and kidney (b, d) and renal injury markers in plasma (e) of T3- or vehicle-pretreated brain-dead rats. Each lane represents an
independent experiment. Results are presented as mean± SD (N = 7 per group) (∗∗p < 0 01).
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Therefore, beneﬁts of oxygen addition to HMP solution are
currently being investigated. Animal studies on liver and
kidney HMP indicate that oxygenated HMP reduced mito-
chondrial ﬂux and subsequent ROS production [91–93].
ROS production is further reduced when grafts are perfused
at higher temperatures, such as subnormothermic (25°C) or
normothermic (37°C) temperatures [94, 95]. Unfortunately,
the eﬀects of HMP on autophagy remain unexplored
(Figure 2).
3.4. Autophagy and Oxidative Stress in the Recipient. As the
extent of the oxidative response is dependent on ischemic
duration, it is possible that the role of autophagy during
IRI is dependent on the extent of oxidative stress. In this
case, mild IR stress would trigger protective autophagy to
counteract the oxidative damage experienced, for example,
through autophagy-speciﬁc degradation of mitochondria
(mitophagy). Regulation of mitophagy is thought to occur
via oxidation of cardiolipin [29, 96–98], which plays a cen-
tral role by mediating increased mitochondrial ROS release
which serves as the signal for mitophagy initiation [99].
However, upon a very strong oxidative response (during
severe reperfusion injury), an energy-dependent process as
autophagy is not advised. In this case, autophagy stimula-
tion could deprive much-needed energy, induce still elusive
autophagy-dependent cell death mechanisms [100], or lead
to the production of toxic lipofuscin (Figure 2) [74].
In the liver, IRI induced oxidative stress, autophagy, and
apoptosis. These eﬀects were attenuated by pretreatment with
the antioxidant astaxanthin, potentially via modulation of the
MAPK protein family [101]. In a study on renal IRI, increased
oxidant production and autophagy markers were evident
which suggests a tight and direct relationship between these
two processes in which autophagy serves a protective role
against renal oxidative damage [102]. In the heart, autophagic
ﬂux was analyzed during IRI in the presence of either H2O2 or
the antioxidant N-2-mercaptopropionyl glycine (MPG).
H2O2 increased, while MPG decreased autophagic ﬂux,
suggesting that autophagy is regulated by oxidative signals
during cardiac IR. Interestingly, autophagy attenuation (by
using heterozygous beclin 1+/− mice) improved injury in
this experimental setting [103]. Altogether, these ﬁndings
imply that oxidative signals inﬂuence autophagy during IR
and might be responsible for the exact role (protective or
detrimental) autophagy plays in IRI, depending on the type
of organ.
Several modulators of oxidative stress and autophagy
have been clinically tested or are commonly used following
transplantation. One method to combat the oxidative burst
in recipients is ischemic postconditioning (IPoC), a tech-
nique that involves the temporal cessation of blood ﬂow to
a remote tissue such as a limb or locally via constriction of
a nearby aﬀerent artery. Despite promising preclinical
results of local [104] and remote IPoC [105], clinical trials
investigating both techniques did not report improved renal
function after transplantation [104, 106]. Interestingly, IPoC
also stimulates autophagy in the heart [107, 108], but this
seems to depend on the postreperfusion time [109]. A
clinical study on the addition of the antioxidant human
recombinant SOD showed decreased rejection rates and
improved survival following cadaveric kidney transplanta-
tion, despite mixed preclinical results [17, 110]. These
results might be autophagy-dependent, as SOD overexpres-
sion resulted in attenuation of starvation-induced autophagy
and apoptosis [111].
Many of the compounds given to transplant recipients as
part of their immunosuppressive regimen also modulate
autophagy. These include calcineurin inhibitors cyclosporine
and tacrolimus, mTOR inhibitors sirolimus (rapamycin) and
everolimus, mycophenolate mofetil (MMF), and corticoste-
roids [55, 112]. Cyclosporine is a known autophagy inducer
that has now largely been replaced by tacrolimus as the
treatment of choice in most European and American
transplantation centers, mostly because of its proposed neph-
rotoxic side eﬀects [112]. Interestingly, these side eﬀects are
thought to be related to increased autophagic clearance and
autophagosome formation, phenomena possibly mediated
via oxidative stress and apoptosis [92, 113]. Tacrolimus, on
the other hand, was recently identiﬁed as an autophagy mod-
ulator that acts via activation of transcription factor EB,
which in turn increases the expression of both autophagy
and lysosomal genes [114, 115]. However, it is likely that this
is associated with a mild, beneﬁcial induction of oxidative
stress [116]. The use of rapamycin as well as second genera-
tion mTOR inhibitors such as everolimus and deferolimus
has been used as part of immunosuppressive therapy mostly
for their ability to limit T-cell proliferation, but these
compounds also inﬂuence autophagy by means of mTOR
inhibition. However, the use of rapamycin in animal models
of renal IRI and transplantation has yielded questionable
results. Some studies suggest that rapamycin improves mito-
chondrial homeostasis and, subsequently, reduces ROS
production and cellular senescence [46]. On the contrary, a
study on renal transplant recipients suﬀering from DGF
shows that patients who received rapamycin had signiﬁcantly
lower chance to resolve DGF [117]. Interestingly, combined
Brain death
Oxidative stress
Cellular
(e.g, mitochondrial)
dysfunction
Apoptosis
Cellular injury
Autophagy
Increased mitochondrial
activity and ROS production
T3
Figure 5: Proposed mechanism of T3 preconditioning during brain
death in the liver.
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treatment with tacrolimus or mycophenolate mofetil (MMP),
an immunosuppressive drug that is known to activate
chaperone-mediated autophagy, enhanced the positive
eﬀects of rapamycin [55, 118]. The mixed eﬀect of rapamycin
treatment might be attributed to the amount of injury and
subsequent extent of autophagy activation [55]. Finally, cor-
ticosteroids have been part of most postoperative and main-
tenance immunosuppressive regimens over the past years
[119]. Interestingly, methylprednisolone (MP) both sup-
presses and stimulates autophagy in animal models [55]. This
diﬀerence could be related to the extent of the preceding
injury, or could be dose- and time-dependent, as MP treat-
ment has opposite eﬀects on oxidative injury when it is
administered acutely (beneﬁcial) or chronically (damaging)
in rat lungs [120]. If and how MP aﬀects autophagy modula-
tion posttransplantation and whether this is inﬂuenced by
oxidative signals remains to be elucidated.
4. Conclusion
Oxidative stress is an important component of the transplan-
tation process as well as a known inducer of autophagy.
Although the exact mechanism behind the complex recipro-
cal relationship between oxidative stress and autophagy is
only beginning to be understood, it seems to play a major role
in the diﬀerent roles autophagy and oxidative signals seem to
play during transplantation. The potential protective proper-
ties of autophagy and low levels of oxidative stress, yet detri-
mental eﬀects when excessive activation occurs (Figure 2),
make these two processes interesting therapeutic or diagnos-
tic targets in each step of the transplantation process, while
their tight interaction supports the possibility to target both
pathways with only one compound. However, how these pro-
cesses are preferentially modulated depends on the speciﬁc
step in the transplantation process, the type of organ, the
age and gender of the donor, the ischemic time, and other
contributing factors. Therefore, future research should try
and decipher the complex, intertwined relationship of oxida-
tive stress and autophagy during the transplantation process.
Finding the optimal balance between autophagic and
oxidative processes is crucial for the optimization of cellular
longevity and thereby graft survival.
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